Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyorin Snags Rights to Genetically Modified Adipocytes for Fabry Disease
June 20, 2022
- EMA Starts Review of Aripiprazole 2-Month Injectable: Otsuka/Lundbeck
June 20, 2022
- Kissei-Originated Fibroid Drug Approved in Europe
June 20, 2022
- Samsca Authorized Generic Hits Shelves in Japan
June 20, 2022
- Taisho’s Lusefi OD Film Now Available in Japan
June 20, 2022
- Takeda Founding Family to Vote against Foreign Leadership
June 17, 2022
- Patent Rows Don’t Stop Generic Players; Single Entries, AG Non-Launches Seen in June Listing
June 17, 2022
- Nihon Medi-Physics Launches AMED-Funded Project to Develop Antibody-RI Conjugates
June 16, 2022
- Ajovy Auto-Injector Approved in Japan: Otsuka
June 16, 2022
- Shionogi to Expand Access for Cefiderocol in Low- and Middle-Income Nations
June 16, 2022
- Asahi Kasei Snags Rights to Tsukuba Upstart’s CKD Drug Candidate
June 15, 2022
- Daiichi Sankyo Kicks Off PIII to Test ADC Follow-Up for Triple-Negative Breast Cancer
June 15, 2022
- Sanofi Set for Dupixent’s Pediatric Eczema Filing in Japan after Positive Data
June 15, 2022
- Otsuka Ties Up with xFOREST on RNA Structure-Targeted Drug Discovery
June 14, 2022
- Authorized Generics Gain Ground amid Quality Woes, Candesartan AG Share Up 10 Points
June 14, 2022
- Quizartinib Cuts Risk of Death by 22.4% in 1st Line AML: Daiichi Sankyo
June 14, 2022
- FDA Accepts Resubmission for Santen/Ube’s Glaucoma Med
June 13, 2022
- Kasper Bødker Mejlvang Tapped as New Novo Japan Chief
June 13, 2022
- AstraZeneca Japan Chief Stefan Woxström Standing Down, Successor Yet to Be Named
June 13, 2022
- Takeda’s Dengue Vaccine Proves 4.5-Year Protection
June 10, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…